Fortis Healthcare Limited
FORTIS
Rangering i aksjer
#3027
Established in 1996 and headquartered in Gurugram, India, Fortis Healthcare... Established in 1996 and headquartered in Gurugram, India, Fortis Healthcare Limited operates as an integrated provider of healthcare services. The company extends its offerings, which encompass secondary, tertiary, and quaternary medical care, across India, the United Arab Emirates, Sri Lanka, and other international markets. Its diverse healthcare infrastructure includes a network of hospitals, diagnostic facilities, and specialized day-care centers. Fortis delivers expertise across a broad spectrum of medical disciplines, including cardiology, cosmetic and dental sciences, dermatology, endocrinology, emergency medicine, ENT, fetal medicine, gastroenterology and hepatology, general surgery, haematology, infertility treatment, internal medicine, mental and behavioral health, nephrology, neurosurgery, neurointervention, neurology, obstetrics and gynaecology, oncology, ophthalmology, orthopedics, pediatrics, physiotherapy, plastic surgery, pulmonology, radiology, rheumatology, thoracic surgery, transplant medicine, urology, and numerous other supporting specialties. By March 31, 2022, the company managed 26 hospitals, housing approximately 4,300 operational beds, in addition to around 426 diagnostic centers and laboratories, complemented by 2,550 collection centers.
Aksjekurs
$8.00
Markedsverdi
$6.04B
Endring (1 dag)
-1.73%
Endring (1 år)
-35.85%
Land
IN
Handel Fortis Healthcare Limited (FORTIS)
Kategori
Healthcare
P/E-forhold for Fortis Healthcare Limited (FORTIS)
P/E-forhold per October 2026 TTM: 54.45
Ifølge Fortis Healthcare Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 54.45. Ved slutten av 2024 hadde selskapet en P/E på 54.07.
P/E-forholdshistorikk for Fortis Healthcare Limited fra 2002 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 54.45 | -18.88% |
| 2025 | 67.12 | 24.12% |
| 2024 | 54.07 | 62.25% |
| 2023 | 33.33 | -15.61% |
| 2022 | 39.49 | -128.83% |
| 2021 | -136.98 | -183.33% |
| 2020 | 164.39 | -658.59% |
| 2019 | -29.43 | 259.86% |
| 2018 | -8.18 | -129.63% |
| 2017 | 27.60 | -106.07% |
| 2016 | -454.80 | 516.52% |
| 2015 | -73.77 | -243.67% |
| 2014 | 51.35 | 302.61% |
| 2013 | 12.75 | -85.73% |
| 2012 | 89.35 | 14.34% |
| 2011 | 78.14 | -53.98% |
| 2010 | 169.81 | -18.80% |
| 2009 | 209.12 | -316.02% |
| 2008 | -96.81 | 47.26% |
| 2007 | -65.74 | -41.19% |
| 2006 | -111.78 | -85.13% |
| 2005 | -751.47 | -19.81% |
| 2004 | -937.07 | 191.12% |
| 2003 | -321.88 | 17.26% |
| 2002 | -274.51 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| 15.70 | -71.16% |
US
|
|
| - | - |
DE
|
|
| 10.40 | -80.90% |
US
|
|
| 32.07 | -41.10% |
SA
|
|
| 20.00 | -63.27% |
BR
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.